AxoGen appoints CEO Karen Zaderej to additional role of Chairman of the Board alongside Amy Wendell as Lead Director

– USA, FL – AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that its Board of Directors has elected Karen Zaderej as Chairman of the Board in addition to her current role as President and Chief Executive Officer (CEO), effective immediately. Zaderej succeeds Jamie M. Grooms, who will remain a Director of the Board.

“As the founder of AxoGen, it has been a tremendous privilege to initiate and develop truly revolutionary products that improve quality of life for patients with peripheral nerve damage,” stated Jamie Grooms. “Karen’s twelve years with AxoGen have been marked with tremendous success.  She has built an organization with a clear mission and a culture of high-performance teamwork.  The Board and I are extremely pleased with the company’s success and I am proud to pass the baton to Karen as she leads the team to continue to execute on her vision.”

In her role as Chairman of the Board, Zaderej will lead efforts in developing and implementing the Company’s strategic vision.  AxoGen is creating a platform for nerve repair with innovative solutions and expanding applications to improve the quality of life for patients with peripheral nerve damage.

“I am deeply honored to be named Chairman of AxoGen,” said Zaderej. “We are building a culture that attracts, inspires, motivates, and develops individuals and teams to achieve excellence by embracing our values. We are just getting started, and we have a tremendous opportunity to improve the quality of life and offer hope for patients with debilitating nerve damage.”

“We are indebted to Jamie Grooms for his founding vision and exemplary service as Chairman, added Zaderej. “He continues to be a valuable resource and an insightful advisor, and we are pleased that AxoGen will continue to benefit from his active involvement on our Board of Directors.”

Further, the AxoGen Board of Directors also elected Amy Wendell to the newly created role of Lead Director. The Lead Director facilitates the functioning of the Board of Directors independently of management of the Company and provides independent leadership to the Board of Directors.

About AxoGen

AxoGen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>